Pulsatile drug delivery system for treating morning akinesia
A pulsatile drug delivery system with timed release of levodopa and carbidopa addresses the issue of morning immobility in Parkinson's disease by ensuring synchronized release in the small intestine, enhancing absorption and reducing off-phases, thus improving daily mobility and sleep patterns.
Patent Information
- Application Number
- JP2024125641
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-07-11
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current levodopa treatments for Parkinson's disease, such as immediate and extended release formulations, fail to effectively address morning immobility and motor fluctuations due to unpredictable absorption and delayed onset of action, leading to significant impairment in daily activities and quality of life for patients.
A pulsatile drug delivery system that provides a timed, delayed burst release of levodopa and a dopa decarboxylase inhibitor, such as carbidopa, in the small intestine, ensuring synchronized release patterns to improve absorption and reduce morning immobility.
The system enhances absorption of levodopa, improves nocturnal sleep patterns, and reduces morning immobility in Parkinson's disease patients by providing a synchronized and controlled release of the active ingredients, thereby improving daily mobility and reducing off-phases.
Smart Images

Figure 2024156827000022 
Figure 2024156827000023 
Figure 2024156827000024
Abstract
Description
[Technical field]
[0001] The present invention relates to a pulsatile drug delivery system that allows for delayed burst release of levodopa inhibitors, including carbidopa, and dopa inhibitors in the small intestine, thereby providing improved treatment of morning immobility in Parkinson's disease patients. [Background technology]
[0002] Movement disorders are often due to dysregulation of dopamine neurotransmission. Parkinson's disease (PD) is an example of a movement disorder associated with dysregulation of dopamine neurotransmission and is due to progressive degeneration of dopamine neurons. To replace the lost dopamine, PD motor symptoms are currently treated with oral levodopa (L-dopa, a precursor of dopamine). Oral levodopa must be emptied from the stomach and absorbed in the proximal small intestine. Levodopa is converted to dopamine in the brain and stored in neurons until needed by the body for movement. Levodopa remains the most effective single drug in treating Parkinson's symptoms.
[0003] Most PD patients treated with levodopa have motor fluctuations. Improvement of symptoms after L-dopa administration is defined as "on", whereas recurrence of symptoms, i.e., when levodopa plasma concentrations decrease, is called "off". Off-phases generally occur when the effect from a given levodopa dose wears off prematurely (wearing-off) or when the next L-dopa dose causes a delayed onset of action (delayed-on).
[0004] Motor complications of PD have been reported to occur after several years of treatment with levodopa, resulting in the replacement of long-term responses with short-term responses and the appearance of off-phases. Although the off-phases can be treated with several adjunctive drugs, the delayed onset of the next levodopa dose can significantly increase the duration of the off-phases.
[0005] Morning immobility is a delayed onset of the first daily dose of L-dopa and occurs in approximately 60% of patients on dopaminergic therapy. It is primarily a motor symptom, but has recently been found to be associated with fluctuations in non-motor symptoms.
[0006] Morning immobility can significantly impact the quality of life of PD patients, impairing their ability to carry out basic daily activities.
[0007] Standard oral levodopa therapy is inadequate for the treatment of morning immobility for reasons related to its pharmacodynamics and pharmacokinetics, and because of its short half-life, erratic gastrointestinal absorption, and competitive transport across the blood-brain barrier. One of the first strategies focused on attempts to prolong levodopa plasma levels using long-acting, controlled-release levodopa formulations. Nevertheless, due to delayed gastric emptying, an oral dose of L-dopa may remain in the stomach for an extended period of time before being absorbed in the small intestine. Another approach is to administer levodopa as a solution to shorten gastric transit time and improve onset of effect. Although this approach may be beneficial for some patients with high variability, the clinical utility of liquid levodopa compared with tablets has not been confirmed in controlled clinical trials. To treat morning akinesia and nocturnal hypomotility, many patients use L-dopa occasionally or as needed. However, its clinical utility is limited by a slow or unpredictable onset of effect.
[0008] Alternative parenteral routes of delivery of dopamine therapy, such as subcutaneous apomorphine injections, are used by PD patients in the OFF state to shorten the time to the ON state. However, early morning self-administration of a subcutaneous pen can be cumbersome in severely disabled PD patients. Nasal, pulmonary and sublingual formulations of levodopa are also available.
[0009] Levodopa is most often combined with a dopa decarboxylase inhibitor, such as carbidopa, which blocks the breakdown of levodopa before it can reach the brain and be effective. Carbidopa allows for a much lower dose of levodopa (less than 80%), which helps reduce the side effects of nausea and vomiting. Carbidopa / levodopa tablets are available in immediate-release (IR) and extended-release (ER) forms, as well as in a dissolving tablet that is placed under the tongue. Small, portable infusion pumps deliver carbidopa and levodopa directly into the small intestine.
[0010] Although the ER combination formulation maintains plasma levodopa concentrations in the therapeutic range for longer periods of time, providing patients with longer on-time and better home control and mobility, it has not been established that the ER formulation improves dyskinesias or Total Disease Impact Profile (SIP) scores.
[0011] In some cases, pretreatment with carbidopa prior to levodopa has been suggested to increase levodopa plasma AUC compared to coadministration (see, eg, Leppert et al., 1988).
[0012] Morning immobility is one of the most common and earliest motor complications in PD patients and affects almost all stages of Parkinson's disease. There remains an unmet medical need to improve nighttime sleep patterns and morning immobility in patients with Parkinson's disease in a safe, non-invasive and compliant manner. Summary of the Invention
[0013] The present inventors have developed a pharmaceutical composition that addresses the shortcomings of current formulations containing levodopa and a dopa decarboxylase inhibitor by providing a composition that allows for a timed pulsatile release of these compounds, providing a delayed burst release of a dopa decarboxylase inhibitor such as carbidopa and a delayed burst release of levodopa after a predetermined delay time, preferably separated in time whereby the dopa decarboxylase inhibitor is released before the levodopa, providing a means of treating morning immobility in Parkinson's disease patients.
[0014] Using the disclosed pulsatile drug delivery, patients can improve their nighttime sleep patterns and be free from complete immobility in the morning. Moreover, such compositions can be taken with existing commercial immediate and controlled release levodopa products to provide a daily dosage range for most patients with Parkinson's disease.
[0015] In one aspect, Levodopa and a dopa decarboxylase inhibitor, b. a pulsatile release component that provides a pulsed release of said levodopa and said dopa decarboxylase inhibitor following a predetermined delay period; The present invention provides a pulsatile release pharmaceutical composition comprising:
[0016] Further, one aspect is a. a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; b. a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and Separately or together, In one embodiment, a pulsatile release pharmaceutical composition is provided, wherein the lag time of the first pulsatile release component comprising levodopa is longer than the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor.
[0017] In one embodiment, the dopa decarboxylase inhibitor is selected from the group consisting of carbidopa, benserazide, methyldopa and DFMD (alpha-difluoromethyl-dopa), or a pharma- ceutically acceptable derivative thereof.
[0018] In one embodiment, the pharmaceutical composition is in a multiparticulate form.
[0019] In one embodiment, the pharmaceutical composition comprises one or more additional active pharmaceutical ingredients, either separately or together.
[0020] In one embodiment, the pharmaceutical composition is for use in the treatment of morning immobility in patients with Parkinson's disease. [Brief description of the drawings]
[0021] [Figure 1] Pharmacokinetic profiles of levodopa products; A) standard immediate release product, B) standard controlled release product, and C) proposed delayed pulsatile product. [Diagram 2] Figure 1 shows the release of model compounds from mini-tablets (20-25% weight gain) containing 30% sodium starch glycolate coated with an ethylcellulose film. The lag time was 3-5 hours with 25% coating, achieving 50% release. There is some variability in the data (see Example 1). [Figure 3A] The release of model compounds from mini-tablets (10-25% weight gain) containing 30% sodium starch glycolate coated with an ethylcellulose film. 10% PVA was added as a pore former. The lag time was 3-5 hours with 15% coating, achieving 65% release. The data showed low variability (see examples 2 and 3). [Figure 3B] The release of model compounds from mini-tablets (10-25% weight gain) containing 30% sodium starch glycolate coated with an ethylcellulose film. 20% PVA was added as a pore former. The lag time was 3-5 hours with 20% coating, achieving 70% release. The data showed low variability (see examples 2 and 3). [Figure 4A]Figure 1 shows the release of model compounds from mini-tablets (10-25% weight gain) containing 30% sodium starch glycolate coated with ethylcellulose film. 10% HPMC was added as a pore former. Lag times were achieved with 15% coating at 3-5 hours, with 50% release. Increased film weight correlates with slow release / low burst, and increased pore former correlates with high burst release. The data variability is low (see examples 4 and 5). [Figure 4B] Figure 1 shows the release of model compounds from mini-tablets (10-25% weight gain) containing 30% sodium starch glycolate coated with ethylcellulose film. 20% HPMC was added as a pore former. Lag times were achieved with 20% coating, 3-5 hours, 75% release. Increased film weight correlates with slow release / low burst, and increased pore former correlates with high burst release. Data variability is low (see Examples 4 and 5). [Diagram 5] Figure 1 shows levodopa release from mini-tablets (17.5-25% weight gain) containing 30% sodium starch glycolate coated with ethylcellulose film. 20% HPMC was added as a pore former. The release from the levodopa mini-tablets is well controlled (see Example 9). [Figure 6] Figure 1 shows levodopa release from mini-tablets (10-25% weight gain) containing 30% sodium starch glycolate coated with an ethylcellulose film. 20% HPMC was added as a pore former. Release from levodopa mini-tablets is well controlled. Data from the release of a model compound was included to show a similar release pattern (see Example 8). [Figure 7] Figure 1 shows levodopa release from mini-tablets (10-25% weight gain) containing 10% sodium starch glycolate coated with an ethylcellulose film. 20% HPMC was added as a pore former. Release from levodopa mini-tablets containing low levels of superdisintegrant is not well controlled and shows poor burst release (see Example 10). [Figure 8] Figure 1 shows carbidopa release from mini-tablets (17.5-25% weight gain) containing 40% sodium starch glycolate coated with an ethylcellulose film. 20% HPMC was added as a pore former. The release from the carbidopa mini-tablets is well controlled (see Example 17). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] One aspect is to provide a pharmaceutical composition that provides a timed pulsatile release of levodopa and a dopa decarboxylase inhibitor such as carbidopa in the small intestine, preferably separated by a time whereby the dopa decarboxylase inhibitor such as carbidopa is released in a pulse prior to levodopa, providing a means for treating morning immobility in, for example, Parkinson's disease patients by orally ingesting such a pharmaceutical composition prior to sleep.
[0023] It is recognized that gastric motility is generally somewhat delayed in Parkinson's disease patients, and thus delayed release up to 5 or 6 hours is feasible while the pharmaceutical composition is still in the small intestine. It is believed that delivering the entire dose of levodopa in a burst to the lower part of the small intestine will improve levodopa absorption. Bioabsorption in this area is not possible with currently marketed levodopa products, and therefore the new principle provides Parkinson's patients with a great new opportunity to have overnight levodopa distribution.
[0024] In humans, L-dopa or levodopa (L-3,4-dihydroxyphenylalanine) is synthesized from the amino acid L-tyrosine. L-dopa is a precursor of the neurotransmitters dopamine, noradrenaline and adrenaline and mediates neurotrophic factor release by the brain and central nervous system. L-dopa is sold as a psychotropic drug under the international generic name levodopa and its trade names include Sinemet, Pharmacopa, Atamet, Stalevo, Madopar and Prolopa. L-dopa is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia.
[0025] L-dopa crosses the blood-brain barrier where it is converted to dopamine by aromatic L-amino acid decarboxylase (dopa decarboxylase). Because L-dopa is also converted to dopamine in the peripheral nervous system, leading to excessive peripheral dopamine signaling and adverse effects, it is standard clinical practice to coadminister it with a peripheral dopa decarboxylase inhibitor (DDCI). Combination therapy enhances the central effects of L-dopa by reducing dose dependency by 4-5-fold.
[0026] Dopa decarboxylase inhibitors include carbidopa, benserazide, methyldopa and DFMD (alpha-difluoromethyl-dopa).
[0027] Medications containing carbidopa alone or in combination with L-dopa are trade names Lodosyn (Aton Pharma), Sinemet (Merck Sharp & Dohme Limited), Pharmacopa (Jazz Pharmaceuticals), Atamet (UCB), Stalevo (Orion Corporation), Parcopa, or in combination with benserazide (combined drugs are trade names Madopar or Prolopa).
[0028] Medicines that contain benserazide alone or in combination with L-dopa go by trade names such as Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc. Medicines that contain methyldopa go by trade names such as Aldomet, Aldoril, Dopamet, Dopegyt, etc.
[0029] Pulsatile drug delivery is defined as the rapid and transient release of a specific amount of a molecule within a short period of time immediately followed by a defined off-release period, ie, lag time.
[0030] Pulsatile drug delivery systems (PDDS) deliver drugs at the right time, at the right site of action and in the right amount, where the drug is rapidly and completely released as a pulse (or burst) after a lag time. These products follow a sigmoidal release profile characterized by a period. Such a release pattern is known as pulsatile release. These systems are beneficial for drugs with chronopharmacological behavior that requires nocturnal administration and for drugs that exhibit a first-pass effect. Potential disadvantages include low drug loading capacity and multiple manufacturing steps.
[0031] The lag time is defined as the time between when the dosage form is placed in an aqueous environment and when the active pharmaceutical ingredient begins to be released from the dosage form.
[0032] Pulsatile drug delivery systems can be broadly classified into three categories: 1) Time-controlled pulsatile release systems (delivery systems containing an erodible coating layer) a. Bulk erosion systems. Bulk erosion means that the rate of water intrusion is faster than the rate of degradation. In this case, degradation occurs throughout the polymer sample and proceeds until a critical molecular weight is reached. At this point, the degradation products become small enough to be solubilized and the structure becomes significantly more porous and hydrated. Thus, there is a lag time before the drug can be released, corresponding to the time required to reach the critical molecular weight. b. Surface eroding systems. In this type of system, the reservoir device is coated with a soluble or erodible layer, which dissolves over time and releases the drug after a certain delay time. When this system comes into contact with an aqueous medium, the coating emulsifies or erodes after a delay time. It is independent of gastrointestinal motility, pH, enzymes and gastric retention. The delay time and onset of action are controlled by the thickness and viscosity grade of the polymer used. Examples include delivery systems with rupturable coating layers and capsule-type systems with release control plugs. a. The coating may be a spray coating (eg, a burst film coating or an erodible film coating) or a compression coating. 2) Stimulus-triggered pulsatile release systems: Stimulus-based drug delivery systems release drugs in response to stimuli induced by the biological environment, such as temperature changes (temperature-responsive pulsatile release) and chemical stimuli, such as pH, enzymes or other chemicals (chemical stimuli-triggered pulsatile release). 3) Externally regulated pulsatile release systems: These include electrically responsive delivery systems (prepared from polyelectrolytes and therefore pH responsive as well as electrically responsive), ultrasound stimulated pulsatile release, and magnetically triggered pulsatile release.
[0033] Provided herein is a pulsatile drug delivery system that provides timed pulsatile release of levodopa and a dopa decarboxylase inhibitor. In one embodiment, the pulsatile drug delivery system is a pharmaceutical composition for timed pulsatile release of levodopa and a dopa decarboxylase inhibitor.
[0034] Pharmaceutical composition and pulsatile release pharmaceutical composition may be used interchangeably herein.
[0035] In one embodiment, i) levodopa and a dopa decarboxylase inhibitor, ii) a pulsatile release component that provides a pulsed release of said levodopa and said dopa decarboxylase inhibitor following a predetermined delay period; A pulsatile release pharmaceutical composition is provided comprising:
[0036] In one embodiment, i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and Pulsatile pharmaceutical compositions are provided comprising, separately or together,
[0037] In one embodiment, the lag time of the first pulsatile release component comprising levodopa is longer than the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor.
[0038] In one embodiment, i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and separately or together, wherein the lag time of the first pulsatile release component containing levodopa is longer than the lag time of the second pulsatile release component containing a dopa decarboxylase inhibitor.
[0039] In one embodiment, the dopa decarboxylase inhibitor is selected from the group consisting of carbidopa, benserazide, methyldopa and DFMD (α-difluoromethyl-dopa), or a pharma- ceutically acceptable derivative thereof.
[0040] In one embodiment, the dopa decarboxylase inhibitor is carbidopa, or a pharma- ceutically acceptable derivative thereof.
[0041] In one embodiment, the term levodopa also includes pharma- ceutically acceptable derivatives of levodopa.
[0042] In one embodiment, the term levodopa includes levodopa prodrugs. In one embodiment, the term levodopa includes the levodopa prodrug levodopa methyl ester. In one embodiment, the term levodopa includes the levodopa prodrug XP21279.
[0043] In one embodiment, the term levodopa also includes modified levodopa. In one embodiment, the term levodopa also includes deuterated levodopa (deuterium substituted levodopa).
[0044] In the context of the present invention, the term "pharmaceutically acceptable derivative" includes pharmaceutically acceptable salts, which refers to salts that are not harmful to patients.Such salts include pharmaceutically acceptable base addition salts or acid addition salts, as well as pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts.Pharmaceutically acceptable derivatives further include esters and prodrugs, or other precursors of compounds that can be biologically metabolized to active compounds, or crystalline forms of compounds.
[0045] In one embodiment, the pharmaceutical composition is a time-controlled pulsatile release system, including bulk erosion systems and surface erosion systems.
[0046] In one embodiment, the pharmaceutical composition is a pharmaceutical dosage form. In one embodiment, the pharmaceutical dosage form is a multiparticulate dosage form (multiple unit dosage form).
[0047] Multiparticulate or multiple unit dosage forms are discrete, sub-units, repeated units of drug particles that may or have similar drug release patterns. They can be tailored for pulsatile drug release.
[0048] In one embodiment, the pharmaceutical dosage form is a multiparticulate dosage form comprising a plurality of particles, each particle providing a timed pulsatile release of levodopa and / or a dopa decarboxylase inhibitor.
[0049] In one embodiment, the pharmaceutical dosage form comprises two dosage forms: i) a first dosage form that provides a pulsatile release of levodopa following a predetermined delay time; ii) a second dosage form that provides a pulsed release of a dopa decarboxylase inhibitor following a predetermined delay period; and, separately or together, are multiparticulate dosage forms.
[0050] In one embodiment, the pharmaceutical dosage form comprises two dosage forms: i) a first dosage form that provides a pulsatile release of levodopa following a predetermined delay time; ii) a second dosage form that provides a pulsed release of a dopa decarboxylase inhibitor following a predetermined delay period; A multiparticulate dosage form comprising, separately or together, The lag time of the first dosage form containing levodopa is longer than the lag time of the second dosage form containing a dopa decarboxylase inhibitor.
[0051] In one embodiment, the multiparticulate dosage form is packaged in a capsule, pouch, sachet or stick pack.In one embodiment, the first dosage form containing levodopa and the second dosage form containing dopa decarboxylase inhibitor are packaged in a capsule, pouch, sachet or stick pack.In one embodiment, the capsule is a hard shell capsule, such as a hard capsule gelatin.
[0052] In one embodiment, the multiparticulate dosage form comprises: i) A first dosage form containing levodopa is administered in the following order: 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20-21, 21-22, 22-23, 23-24, 24-25, 25-26, 26-27, 27-28, 28-29, 29-30, 3 0-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, and ii) a second dosage form containing a dopa decarboxylase inhibitor, Includes 29-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, and 190-200.
[0053] The number of dosage forms in a multiparticulate dosage form is determined by factors such as the dose of the active pharmaceutical ingredient and the size of the dosage form.
[0054] In one embodiment, the pharmaceutical dosage forms, such as the first dosage form and the second dosage form, are oral solid dosage forms. In one embodiment, the oral solid dosage forms are selected from the group consisting of tablets, mini tablets, micro tablets, spheres, pellets, granules and capsules.
[0055] In one embodiment, the oral solid dosage form comprises a coating. In one embodiment, the oral solid dosage form comprises a core with a coating. In one embodiment, the core comprises an active pharmaceutical ingredient. In one embodiment, the coating does not contain an active pharmaceutical ingredient.
[0056] In one embodiment, the oral solid dosage form is selected from the group consisting of coated tablets, coated minitablets, coated microtablets, coated spheres, coated pellets, coated granules and coated capsules.
[0057] In one embodiment, the oral solid dosage form comprises a swellable, soluble core.
[0058] In one embodiment, the coating is a film coating.
[0059] In one embodiment, the coating is a semipermeable coating, such as a semipermeable insoluble film coating. Swelling of the core causes the active pharmaceutical ingredient to be released through the semipermeable film coating.
[0060] In one embodiment, the coating is an insoluble coating.
[0061] In one embodiment, the coating is a rupturable coating.
[0062] In one embodiment, the coating is a rupturable insoluble coating, whereby expansion of the core component causes the outer coating to rupture and burst releasing the contained ingredients.
[0063] In one embodiment, the coating is a soluble or erodible coating.
[0064] In one embodiment, the oral dosage form comprises a soluble core coated with an insoluble film, such as an insoluble semipermeable film.
[0065] In one embodiment, the pharmaceutical dosage form is a coated mini-tablet. In one embodiment, the pharmaceutical dosage form is a tablet, such as a coated tablet. In one embodiment, the pharmaceutical dosage form is a tablet, including coated mini-tablets compressed into a tablet.
[0066] In one embodiment, the coating is of the spray coating type. In one embodiment, the coating is of the press coating type.
[0067] In one embodiment, the outer coating comprises a film-forming polymer. In one embodiment, the outer coating comprises a water-insoluble polymer. In one embodiment, the outer coating further comprises a pore former, such as a hydrophilic pore former.
[0068] Minitablets are tablets with a diameter of ≦3 mm and are a new trend in the design of solid dosage forms, which overcome several therapeutic obstacles such as dysphagia and polypharmacy, and also offer several therapeutic advantages such as dose flexibility and combined release patterns.
[0069] In one embodiment, mini-tablets are tablets with a diameter of less than or equal to 3 mm (≦), such as ≦2.5 mm, such as ≦2 mm, such as ≦1.5 mm, for example ≦1 mm. In one embodiment, mini-tablets are tablets with a diameter of 1-1.5 mm, such as 1.5-2 mm, for example 2-2.5 mm, 2.5-3 mm, etc. In one embodiment, mini-tablets are tablets with a diameter of approximately 2 mm.
[0070] In one embodiment, the pharmaceutical composition provides a sigmoid release profile of levodopa and a sigmoid release profile of the dopa decarboxylase inhibitor, preferably in which the lag time of the first pulsatile release of levodopa is also shifted to a longer time for the lag time of the second pulsatile release of the dopa decarboxylase inhibitor.
[0071] The lag time of the pulsatile release component is adjusted to release the levodopa and the dopa decarboxylase inhibitor in the small intestine, for example, in the lower portion of the small intestine.
[0072] In one embodiment, the lag time of the pulsatile release component comprising levodopa and a dopa decarboxylase inhibitor is between 2 and 8 hours, such as between 2 and 3 hours, for example between 3 and 4 hours, such as between 4 and 5 hours, for example between 5 and 6 hours, such as between 6 and 7 hours, for example between 7 and 8 hours.
[0073] The lag time of the first pulsatile release component containing levodopa and the lag time of the second pulsatile release component containing a dopa decarboxylase inhibitor are preferably adjusted to release the active pharmaceutical ingredients in the small intestine, e.g., in the lower part of the small intestine. Preferably, the dopa decarboxylase inhibitor is released prior to the release of levodopa in the small intestine, e.g., in the lower part of the small intestine.
[0074] In one embodiment, the lag time of the first pulsatile release component comprising levodopa is between 2 and 8 hours, such as between 2 and 3 hours, for example between 3 and 4 hours, such as between 4 and 5 hours, for example between 5 and 6 hours, such as between 6 and 7 hours, for example between 7 and 8 hours.
[0075] In one embodiment, the lag time of the first pulsatile release component comprising levodopa is 3 to 6 hours, such as 4 to 6 hours, for example 3 to 5 hours.
[0076] In one embodiment, the lag time of the first pulsatile release component comprising levodopa is at least 2 hours, such as at least 3 hours, such as at least 4 hours.
[0077] In one embodiment, the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor is between 2 and 8 hours, such as between 2 and 3 hours, for example between 3 and 4 hours, such as between 4 and 5 hours, for example between 5 and 6 hours, such as between 6 and 7 hours, for example between 7 and 8 hours.
[0078] In one embodiment, the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor is from 3 to 6 hours, such as from 4 to 6 hours, for example from 3 to 5 hours.
[0079] In one embodiment, the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor is at least 2 hours, such as at least 3 hours, such as at least 4 hours.
[0080] In one embodiment, the lag times of a first dosage form comprising levodopa and a second dosage form comprising a dopa decarboxylase inhibitor are shifted in time, such that the lag time of the first dosage form comprising levodopa is the longest.
[0081] In one embodiment, the lag time of the first dosage form containing levodopa is longer than the lag time of the second dosage form containing the dopa decarboxylase inhibitor, such that the dopa decarboxylase inhibitor is released before levodopa is released.
[0082] In one embodiment, the delay time of the first dosage form containing levodopa is 5 to 90 minutes longer than the delay time of the second dosage form containing a dopa decarboxylase inhibitor, for example 5 to 10 minutes, for example 10 to 15 minutes, for example 15 to 20 minutes, for example 20 to 25 minutes, for example 25 to 30 minutes, for example 30 to 35 minutes, for example 35 to 40 minutes, for example 40 to 45 minutes, for example 45 to 50 minutes, for example 50 to 55 minutes, for example 55 to 60 minutes, for example 60 to 65 minutes, for example 65 to 70 minutes, for example 70 to 75 minutes, for example 75 to 80 minutes, for example 80 to 85 minutes, for example 85 to 90 minutes longer than the delay time of the second dosage form containing a dopa decarboxylase inhibitor.
[0083] In one embodiment, the lag time of the first dosage form containing levodopa is 90 to 240 minutes longer than the lag time of the second dosage form containing a dopa decarboxylase inhibitor, for example 90 to 100 minutes, for example 100 to 110 minutes, for example 110 to 120 minutes, for example 120 to 130 minutes, for example 130 to 140 minutes, for example 140 to 150 minutes, for example 150 to 160 minutes, for example 160 to 170 minutes, for example 170 to 180 minutes, for example 180 to 200 minutes, for example 200 to 220 minutes, for example 220 to 240 minutes longer than the lag time of the second dosage form containing a dopa decarboxylase inhibitor.
[0084] In one embodiment, the lag time of the first dosage form comprising levodopa is at least 5 minutes longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor, such as at least 10 minutes longer, such as at least 15 minutes longer, such as at least 20 minutes longer, such as at least 25 minutes longer, such as at least 30 minutes longer, such as at least 35 minutes, such as at least 40 minutes longer, such as at least 45 minutes, such as at least 50 minutes longer, such as at least 55 minutes, such as at least 60 minutes longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor.
[0085] In one embodiment, the lag time of the first dosage form comprising levodopa is about 10 minutes longer, such as about 15 minutes longer, for example about 20 minutes longer, such as about 25 minutes longer, for example about 30 minutes longer, such as about 35 minutes, for example about 40 minutes longer, such as about 45 minutes, for example about 50 minutes longer, such as about 55 minutes, for example about 60 minutes longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor.
[0086] After a lag time the active pharmaceutical ingredient is released from the pharmaceutical composition or dosage form.
[0087] In one embodiment, the first dosage form containing levodopa is released prior to the second dosage form containing the dopa decarboxylase inhibitor.
[0088] In one embodiment, the first dosage form comprising levodopa is released 5 to 10 minutes before the second dosage form comprising a dopa decarboxylase inhibitor, for example 10 to 15 minutes, for example 15 to 20 minutes, for example 20 to 25 minutes, for example 25 to 30 minutes, for example 30 to 35 minutes, for example 35 to 40 minutes, for example 40 to 45 minutes, for example 45 to 50 minutes, for example 50 to 55 minutes, for example 55 to 60 minutes, for example 60 to 65 minutes, for example 65 to 70 minutes, for example 70 to 75 minutes, for example 75 to 80 minutes, for example 80 to 85 minutes, for example 85 to 90 minutes before.
[0089] In one embodiment, the pharmaceutical composition releases 70-100% of the drug load measured 2-5 hours after the lag phase, i.e., releases 70-100% of the levodopa and / or dopa decarboxylase inhibitor measured 2-5 hours after the lag phase.
[0090] In one embodiment the pharmaceutical composition releases 70-100% of the drug load measured over 2-5 hours, such as 70-75%, for example 75-80%, such as 80-85%, for example 85-90%, such as 90-95%, for example 95-100% of the drug load measured over 2-5 hours.
[0091] In one embodiment, the pharmaceutical composition releases up to 100% of the drug load within 2 hours after the lag phase. In one embodiment, the pharmaceutical composition releases 70%, such as 80%, such as 90%, such as 100% of the drug load within 2 hours after the lag phase. In one embodiment, the pharmaceutical composition releases 70%, such as 80%, such as 90%, such as 100% of the drug load within 2-5 hours, such as within 2 hours, such as within 3 hours, such as within 4 hours, such as within 5 hours after the lag phase.
[0092] Coated tablets In one embodiment, the pharmaceutical dosage form comprises one or more coated tablets comprising levodopa and a dopa decarboxylase inhibitor that provide a pulsatile release of said levodopa and said dopa decarboxylase inhibitor following a predetermined lag time.
[0093] In one embodiment, the pharmaceutical composition is i) a coated tablet that provides a pulsatile release of levodopa following a predetermined delay period; ii) a coated tablet that provides a pulsatile release of a dopa decarboxylase inhibitor following a predetermined delay period; and, separately or together, are multiparticulate dosage forms.
[0094] In one embodiment, the lag time of the coated tablet containing levodopa is longer than the lag time of the coated tablet containing a dopa decarboxylase inhibitor.
[0095] In one embodiment, the coated tablet comprises an active pharmaceutical ingredient and an outer coating.
[0096] Coated tablets include both coated tablets and coated mini-tablets. In one embodiment, the coated tablets are coated tablets. In one embodiment, the coated tablets are coated mini-tablets.
[0097] In one embodiment, the coated tablets comprise a swellable, soluble mini-tablet core.
[0098] In one embodiment, the coated tablet comprises a semipermeable film coating: upon swelling of the core, the active pharmaceutical ingredient is released through the semipermeable film.
[0099] In one embodiment, the coated tablets are coated mini-tablets comprising a semi-permeable film coating. Swelling of the mini-tablet core releases the active pharmaceutical ingredient through the semi-permeable film.
[0100] In one embodiment, the coated tablet comprises a rupturable insoluble coating, whereby expansion of the core component causes the outer coating to rupture and burst releasing the contained ingredients.
[0101] In one embodiment, the coated minitablets containing levodopa comprise a swellable, soluble minitablet core containing levodopa and an outer semipermeable film coating.
[0102] In one embodiment, the coated minitablets comprising a dopa decarboxylase inhibitor comprise a swellable, soluble minitablet core comprising a dopa decarboxylase inhibitor and an outer semipermeable film coating.
[0103] In one embodiment, the coated tablet containing levodopa comprises a swellable, soluble tablet core containing levodopa and a rupturable, insoluble coating.
[0104] In one embodiment, the coated tablet comprising a dopa decarboxylase inhibitor comprises a swellable, soluble tablet core comprising a dopa decarboxylase inhibitor and a rupturable, insoluble coating.
[0105] In one embodiment, the tablet core comprising levodopa comprises: -Levodopa -Super disintegrant, one or more excipients, and -Optionally, an anti-adherent agent It comprises or consists of:
[0106] In one embodiment, the tablet core comprises 25-75% by weight of levodopa, such as 25-30% by weight, for example 30-35% by weight, such as 35-40% by weight, for example 40-45% by weight, such as 45-50% by weight, for example 50-55% by weight, such as 60-65% by weight, for example 65-70% by weight, for example 70-75% by weight of levodopa.
[0107] In one embodiment, the mini tablet core comprises 1-5 mg of levodopa, such as 1-1.25 mg, for example 1.25-1.5 mg, for example 1.5-1.75 mg, for example 1.75-2 mg, for example 2-2.25 mg, for example 2.25-2.5 mg, for example 2.5-2.75 mg, for example 2.75-3 mg, for example 3-3.25 mg, for example 3.25-3.5 mg, for example 3.5-3.75 mg, for example 3.75-4 mg, for example 4-4.25 mg, for example 4.25-4.5 mg, for example 4.5-4.75 mg, for example 4.75-5 mg of levodopa. In one embodiment, the mini tablet core comprises 2.5-3.5 mg of levodopa. In one embodiment, the mini tablet core comprises at least 2, for example at least 2.5 mg of levodopa.
[0108] In one embodiment, the tablet core comprising a dopa decarboxylase inhibitor comprises -dopa decarboxylase inhibitors, -Super disintegrant, one or more excipients, and -Optionally, an anti-adherent agent It comprises or consists of:
[0109] In one embodiment, the tablet core comprises 25-75% by weight of dopa decarboxylase inhibitor, such as 25-30% by weight, for example 30-35% by weight, such as 35-40% by weight, for example 40-45% by weight, such as 45-50% by weight, for example 50-55% by weight, such as 60-65% by weight, for example 65-70% by weight, for example 70-75% by weight of dopa decarboxylase inhibitor.
[0110] Superdisintegrants are agents used in tablet pharmaceuticals that cause the tablet to disintegrate on contact with moisture, releasing its medicinal substance.
[0111] In one embodiment, the tablet core comprises 15-50% by weight of superdisintegrant, such as 15-20% by weight, such as 20-25% by weight, for example 25-30% by weight, such as 30-35% by weight, for example 35-40% by weight, such as 40-45% by weight, for example 45-50% by weight of superdisintegrant. In one embodiment, the tablet core comprises at least 20% by weight of superdisintegrant, such as at least 25% by weight, for example at least 30% by weight of superdisintegrant. In one embodiment, the tablet core comprises approximately 30% by weight of superdisintegrant.
[0112] In one embodiment, the superdisintegrant is selected from crosslinked starch, crosslinked cellulose, crosslinked PVP (polyvinylpyrrolidone), crosslinked alginic acid, soy polysaccharides, calcium silicate, gellan gum, and xanthan gum.
[0113] In one embodiment, the tablet core comprises one or more superdisintegrants selected from the group consisting of sodium starch glycolate, croscarmellose sodium, crospovidone, crospovidone XL, crospovidone CL and low-substituted hydroxypropylcellulose (L-HPC). In one embodiment, the superdisintegrant is sodium starch glycolate.
[0114] Excipients are pharmacologically inactive (or chemically inactive) substances that are compounded with the active pharmaceutical ingredient of a drug. Excipients are typically used to increase the bulk of formulations containing the active pharmaceutical ingredient (and thus are often called "bulking agents," "fillers," or "diluents"), allowing for convenient and accurate dispensing of the drug substance to produce the dosage form.
[0115] In one embodiment the tablet core comprises 10-50% by weight of excipients, such as 10-15% by weight, for example 15-20% by weight, such as 20-25% by weight, for example 25-30% by weight, such as 30-35% by weight, for example 35-40% by weight, such as 40-45% by weight, for example 45-50% by weight of excipients.
[0116] In one embodiment, the excipient acts as a binder, filler, solid carrier, diluent, flavoring, solubilizer, lubricant, glidant, suspending agent, preservative, anti-adherent, wetting agent, disintegrant or adsorbent or a combination thereof.
[0117] In one embodiment, the tablet core comprises one or more fillers, such as a filler selected from the group consisting of calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, compressible sugar, dextrates, dextrin, dextrose, ethyl cellulose, fructose, isomalt, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, microcrystalline cellulose (MCC), polydextrose, sodium alginate, sorbitol, talc, and xylitol.
[0118] In one embodiment, the tablet core comprises one or more binders such as a binder selected from the group consisting of acacia, alginic acid, carbomer, sodium carboxymethylcellulose, carrageenan, cellulose acetate phthalate, chitosan, copovidone, dextrates, dextrin, dextrose, ethylcellulose, gelatin, guar gum, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylstarch, hydroxypropylmethylcellulose (HPMC or hypromellose), methylcellulose, microcrystalline cellulose (MCC), poloxamer, polydextrose, polyethylene oxide, povidone, sodium alginate, sucrose, starch, pregelatinized starch, and maltodextrin.
[0119] In one embodiment, the tablet core comprises one or more liquid binders. In one embodiment, the minitablet core comprises one or more liquid binders selected from the group consisting of pregelatinized starch, HPMC, methylcellulose and gelatin.
[0120] In one embodiment the tablet core comprises 5-25% by weight of binder, such as 5-7.5% by weight, for example 7.5-10% by weight, such as 10-12.5% by weight, for example 12.5-15% by weight, such as 15-17.5% by weight, for example 17.5-20% by weight, such as 20-22.5% by weight, for example 22.5-25% by weight of binder.
[0121] In one embodiment the tablet core comprises 1-20 wt% liquid binder, such as 1-2.5 wt%, for example 2.5-5 wt%, such as 5-7.5 wt%, for example 7.5-10 wt%, such as 10-12.5 wt%, for example 12.5-15 wt%, such as 15-17.5 wt%, for example 17.5-20 wt% of liquid binder.
[0122] In one embodiment, the minitablet core comprises microcrystalline cellulose (MCC) and pregelatinized starch.
[0123] In one embodiment, the tablet core comprises 5-25% by weight of microcrystalline cellulose, such as 5-7.5% by weight, for example 7.5-10% by weight, for example 10-12.5% by weight, for example 12.5-15% by weight, for example 15-17.5% by weight, for example 17.5-20% by weight, for example 20-22.5% by weight, for example 22.5-25% by weight. In one embodiment, the mini tablet core comprises 10-20% by weight of microcrystalline cellulose.
[0124] In one embodiment the tablet core comprises 1-20% by weight of pregelatinised starch, such as 1-2.5% by weight, such as 2.5-5% by weight, for example 5-7.5% by weight, such as 7.5-10% by weight, for example 10-12.5% by weight, such as 12.5-15% by weight, for example 15-17.5% by weight, such as 17.5-20% by weight of pregelatinised starch. In one embodiment the mini tablet core comprises 5-15% by weight, such as 5-10% by weight of pregelatinised starch.
[0125] In one embodiment the tablet core comprises an anti-adherent agent, such as 0.25 to 0.50 wt% of anti-adherent agent, for example 0.50 to 0.75 wt%, such as 0.75 to 1.0 wt%, for example 1.0 to 1.25 wt%, such as 1.25 to 1.50 wt%, for example 1.50 to 1.75 wt%, such as 1.75 to 2.0 wt% of anti-adherent agent.
[0126] In one embodiment, the anti-adherent agent is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, hydrogenated castor oil, hydrogenated vegetable oil, medium chain glycerides, palmitic acid, poloxamer, polyethylene glycol, stearic acid and talc, hi one embodiment, the anti-adherent agent is magnesium stearate.
[0127] In one embodiment, the tablet core comprising levodopa comprises: 25-75% by weight of levodopa, for example 25-30% by weight, for example 30-35% by weight, for example 35-40% by weight, for example 40-45% by weight, for example 45-50% by weight, for example 50-55% by weight, for example 60-65% by weight, for example 65-70% by weight, for example 70-75% by weight of levodopa; - 15-50 wt. % of a superdisintegrant, for example 15-20 wt. %, such as 20-25 wt. %, for example 25-30 wt. %, such as 30-35 wt. %, for example 35-40 wt. %, for example 40-45 wt. %, for example 45-50 wt. % of a superdisintegrant; 10-50% by weight of excipients, for example 10-15% by weight, such as 15-20% by weight, for example 20-25% by weight, for example 25-30% by weight, for example 30-35% by weight, such as 35-40% by weight, for example 40-45% by weight, for example 45-50% by weight of excipients; 0-2 wt. % of an anti-adhesion agent, for example 0.25-0.50 wt. % of an anti-adhesion agent, for example 0.50-0.75 wt. %, for example 0.75-1.0 wt. %, for example 1.0-1.25 wt. %, for example 1.25-1.50 wt. %, for example 1.50-1.75 wt. %, for example 1.75-2.0 wt. % of an anti-adhesion agent; It comprises or consists of:
[0128] In one embodiment, the tablet core comprising levodopa comprises: - 40 to 60% by weight of levodopa; - 20 to 40% by weight of a superdisintegrant; 10 to 30% by weight of an excipient; - 0.5 to 1.5% by weight of an anti-adhesive agent; It comprises or consists of:
[0129] In one embodiment, the tablet core comprising levodopa comprises: 40 to 60% by weight, for example 45 to 55% by weight, of levodopa; - 20 to 40% by weight, for example 25 to 35% by weight, of sodium starch glycolate, - 5 to 25% by weight, for example 10 to 20% by weight, of crystalline cellulose; - 1 to 20% by weight, for example 5 to 10% by weight, of pregelatinized starch, - 0.5 to 1.5% by weight, for example 1% by weight, of magnesium stearate; It comprises or consists of:
[0130] In one embodiment, the tablet core comprising a dopa decarboxylase inhibitor comprises -25-75% by weight of a dopa decarboxylase inhibitor, for example 25-30% by weight, for example 30-35% by weight, for example 35-40% by weight, for example 40-45% by weight, for example 45-50% by weight, for example 50-55% by weight, for example 60-65% by weight, for example 65-70% by weight, for example 70-75% by weight of a dopa decarboxylase inhibitor; - 15-50 wt. % of a superdisintegrant, for example 15-20 wt. %, such as 20-25 wt. %, for example 25-30 wt. %, such as 30-35 wt. %, for example 35-40 wt. %, for example 40-45 wt. %, for example 45-50 wt. % of a superdisintegrant; 10-50% by weight of excipients, for example 10-15% by weight, such as 15-20% by weight, for example 20-25% by weight, for example 25-30% by weight, for example 30-35% by weight, such as 35-40% by weight, for example 40-45% by weight, for example 45-50% by weight of excipients; 0-2 wt. % of an anti-adhesion agent, for example 0.25-0.50 wt. % of an anti-adhesion agent, for example 0.50-0.75 wt. %, for example 0.75-1.0 wt. %, for example 1.0-1.25 wt. %, for example 1.25-1.50 wt. %, for example 1.50-1.75 wt. %, for example 1.75-2.0 wt. % of an anti-adhesion agent; It comprises or consists of:
[0131] In one embodiment, the tablet core comprises carbidopa.
[0132] In one embodiment, coated tablets are prepared by granulation, compression, followed by film coating.
[0133] In one embodiment, the coated mini-tablets are compressed to form a tablet, hi one embodiment, the coated mini-tablets are packaged in a capsule, pouch, sachet or stick pack.
[0134] coating It is envisaged that an outer coating is applied to increase the weight of the tablet to a certain extent, thereby delaying the release of the substance. Weight gain or weight gain as defined herein is the increase relative to the tablet core weight.
[0135] In one embodiment the outer coating is applied to increase the weight of the minitablet core by 10-40% by weight, such as 10-12.5% by weight, for example 12.5-15% by weight, such as 15-17.5% by weight, for example 17.5-20% by weight, such as 20-22.5% by weight, for example 22.5-25% by weight, such as 25-27.5% by weight, for example 27.5-30% by weight, such as 30-32.5% by weight, for example 32.5-35% by weight, such as 35-37.5% by weight, for example 37.5-40% by weight. In one embodiment this applies to minitablet cores comprising levodopa and to minitablet cores comprising a dopa decarboxylase inhibitor.
[0136] In one embodiment, the outer coating is applied to increase the weight of the minitablet core by 17.5% to 25% by weight, for example 20 to 25% by weight.
[0137] In one embodiment the outer coating is applied to increase the weight of the minitablet core by at least 15% by weight, such as at least 17.5% by weight, such as at least 20% by weight, such as at least 22.5% by weight, such as at least 25% by weight.
[0138] In one embodiment the outer coating is applied to increase the weight of the minitablet core by approximately 15% by weight, such as approximately 17.5% by weight, for example approximately 20% by weight, such as approximately 22.5% by weight, for example approximately 25% by weight, such as approximately 27.5% by weight, for example approximately 30% by weight.
[0139] In one embodiment the outer coating is applied to increase the weight of the tablet core (not the minitablets) by 1-20% by weight, such as 1-2.5% by weight, for example 2.5-5% by weight, such as 5-7.5% by weight, for example 7.5-10% by weight, such as 10-12.5% by weight, for example 12.5-15% by weight, such as 15-17.5% by weight, for example 17.5-20% by weight. In one embodiment this applies to tablet cores comprising levodopa and to tablet cores comprising a dopa decarboxylase inhibitor.
[0140] In one embodiment, an outer coating is applied to the tablet core containing levodopa to achieve the desired lag time as defined elsewhere herein.
[0141] In one embodiment, an outer coating is applied to the tablet core containing the dopa decarboxylase inhibitor to achieve the desired lag time as defined elsewhere herein.
[0142] In one embodiment, the weight gain of the outer coating of the tablet core containing levodopa and the weight gain of the outer coating of the tablet core containing the dopa decarboxylase inhibitor are adjusted to release levodopa prior to the dopa decarboxylase inhibitor, as specified herein.
[0143] In one embodiment, the weight gain of the outer coating of the tablet core comprising levodopa is higher than the weight gain of the outer coating of the tablet core comprising the dopa decarboxylase inhibitor.
[0144] In one embodiment, the weight gain of the outer coating of a tablet core comprising levodopa is about 1 to 25% higher than the weight gain of the outer coating of a tablet core comprising a dopa decarboxylase inhibitor, for example about 1 to 2%, such as about 2 to 3%, for example about 3 to 4%, for example about 4 to 5%, for example about 5 to 6%, for example about 6 to 7%, for example about 7 to 8%, for example about 8 to 9%, for example about 9 to 10%, for example about 10 to 11%, for example about 11 to 12%, for example about 12 to 13%, for example about 13 to 14%, for example about 14 to 15%, for example about 15 to 16%, for example about 16 to 17%, for example about 17 to 18%, for example about 18 to 19%, for example about 19 to 20%, for example about 20 to 21%, for example about 21 to 22%, for example about 22 to 23%, for example about 23 to 24%, for example about 24 to 25% higher.
[0145] In one embodiment, the coating is an insoluble, rupturable film.
[0146] In one embodiment, the coating is an insoluble, semi-permeable film.
[0147] In one embodiment, the coating is a semipermeable film.
[0148] In one embodiment, the coating comprises a film-forming polymer.
[0149] In one embodiment, the coating comprises a water insoluble polymer.
[0150] In one embodiment, the coating comprises one or more of ethyl cellulose, hydroxypropyl cellulose, cellulose acetate, acrylic polymers, enteric polymers, hypromellose acetate succinate, shellac, waxes, and ethyl cellulose dispersions.
[0151] In one embodiment, the coating comprises ethyl cellulose.
[0152] In one embodiment, the coating further comprises a pore former, for example a hydrophilic pore former, hi one embodiment, the pore former is selected from the group consisting of polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG).
[0153] In one embodiment, the coating comprises a water insoluble polymer and a hydrophilic pore former.
[0154] In one embodiment, the coating comprises ethyl cellulose and a pore former, e.g., a pore former selected from PVA, HPMC, PVP, and PEG. In one embodiment, the outer coating comprises ethyl cellulose and PVA. In one embodiment, the outer coating comprises ethyl cellulose and HPMC.
[0155] In one embodiment the coating comprises 5-40% by weight of pore former, such as 5-10% by weight, for example 10-15% by weight, such as 15-20% by weight, for example 20-25% by weight, such as 25-30% by weight, for example 30-35% by weight, for example 35-40% by weight of pore former. In one embodiment the outer coating comprises 10-30% by weight, such as 15-25% by weight of pore former.
[0156] In one embodiment, the coating ratio of the film-forming polymer (or water-insoluble polymer) and the hydrophilic pore former is about 10 / 90, 15 / 85, 20 / 80, 25 / 75 or 30 / 70.
[0157] In one embodiment, the coating comprises approximately 80% by weight ethyl cellulose and approximately 20% by weight HPMC, hi one embodiment, the outer coating comprises approximately 80% by weight ethyl cellulose and approximately 20% by weight PVA.
[0158] Administration and Dosage The pharmaceutical composition disclosed herein is preferably administered to an individual in need of treatment in a pharmacologic effective amount.The therapeutically effective amount of compound or active pharmaceutical ingredient is an amount sufficient to treat, prevent, reduce the risk of, alleviate or partially suppress the clinical symptoms of a certain disease or movement disorder and its complications.The effective amount for a specific therapeutic purpose depends on the severity and type of movement disorder, and the weight and general condition of the subject.
[0159] A pharmaceutical composition according to the present disclosure may be administered several times per day, such as 1-4 times per day, such as 1-3 times per day, such as 1-2 times per day, such as 2-4 times per day, such as 2-3 times per day. In certain embodiments, the pharmaceutical composition is administered once per day, such as twice per day, such as three times per day, such as four times per day.
[0160] Administration can occur for a limited period of time, or administration can be chronic, e.g., from the onset of diagnosis, chronically, e.g., for the life of the individual, or for as long as the individual benefits from administration, i.e., while the movement disorder is present or at increased risk of developing a movement disorder.
[0161] In one embodiment, the pharmaceutical composition will be administered for as long as the movement disorder is present or there is an increased risk of developing a movement disorder.
[0162] The concentration of each of the active pharmaceutical ingredients of the pharmaceutical composition of the present invention, namely, i) levodopa and ii) dopa decarboxylase inhibitor, is optimized to achieve an appropriate dosage of each active pharmaceutical ingredient.
[0163] In one embodiment, the pharmaceutical composition comprises levodopa in an amount between 1 mg and 1000 mg per dose, e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, or 1000 mg of levodopa per dose, which may be comprised of one or more dosage forms containing said amounts of levodopa.
[0164] Similarly, in one embodiment the pharmaceutical composition further comprises a dopa decarboxylase inhibitor in an amount of 1-250 mg per dose, e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200 or 250 mg per dose, which doses may consist of one or more dosage forms containing said amounts of dopa decarboxylase inhibitor.
[0165] In certain embodiments, the amount of levodopa in the pharmaceutical composition is about 100 mg and the amount of dopa decarboxylase inhibitor, such as carbidopa, is about 25 mg.
[0166] In one embodiment, the pharmaceutical composition is i) a first dosage form comprising about 100 mg of levodopa in 10 to 50 mini-tablets, for example in 20 to 40 mini-tablets, for example in about 33 mini-tablets; ii) a second dosage form comprising about 25 mg of a dopa decarboxylase inhibitor, such as carbidopa, in 5 to 15 mini-tablets, for example in about 10 mini-tablets; A multiparticulate dosage form comprising:
[0167] Treatment of morning immobility Oral levodopa generally provides strong and reliable symptom relief when it is first started, but after months or years of taking the drug, most Parkinson's disease patients begin to have a variable response to levodopa.
[0168] The fluctuating response can be divided into "on" episodes, when the drug works well and controls the symptoms of Parkinson's disease, and "off" episodes, when the drug is ineffective or has a delayed effect and does not adequately control the symptoms of Parkinson's disease. Morning immobility is one form of "off" episode. Symptoms of morning immobility include morning tremor, bradykinesia, muscle rigidity, freezing and falls, and difficulty moving and walking.
[0169] One aspect is to provide a pulsatile release pharmaceutical composition as defined herein for use in the treatment of morning immobility in patients with Parkinson's disease.
[0170] One aspect relates to a method for the treatment of morning immobility in patients with Parkinson's disease. i) levodopa and a dopa decarboxylase inhibitor, ii) a pulsatile release component that provides a pulsed release of said levodopa and said dopa decarboxylase inhibitor following a predetermined delay period; The present invention provides a pulsatile release pharmaceutical composition comprising:
[0171] One aspect relates to a method for the treatment of morning immobility in patients with Parkinson's disease. i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and and optionally, wherein the lag time of the first pulsatile release component containing levodopa is longer than the lag time of the second pulsatile release component containing a dopa decarboxylase inhibitor.
[0172] One aspect relates to the manufacture of a medicament for the treatment of morning immobility in a patient with Parkinson's disease, comprising: i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and and, separately or together, optionally wherein the lag time of the first pulsatile release component containing levodopa is longer than the lag time of the second pulsatile release component containing a dopa decarboxylase inhibitor.
[0173] In one aspect, a method of treating morning immobility in a Parkinson's disease patient is provided, the method comprising: i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and separately or together, optionally wherein the lag time of the first pulsatile release component containing levodopa is longer than the lag time of the second pulsatile release component containing a dopa decarboxylase inhibitor.
[0174] Also provided is a pharmaceutical composition as defined herein for use in a) a method of improving nighttime sleep patterns in a patient with Parkinson's disease, b) a method of reducing sleep disturbances involved in the induction of early morning off periods, c) a method of providing overnight distribution of levodopa in a patient with Parkinson's disease, d) a method of shortening off periods in a patient with Parkinson's disease, e) a method of reducing the nocturnal decline in dopamine activity, and / or f) a method of prolonging on periods in a patient with Parkinson's disease.
[0175] Also provided is a pharmaceutical composition as defined herein for use in a method for reducing motor and non-motor symptoms associated with morning immobility in a patient with Parkinson's disease.
[0176] The main non-motor symptoms associated with morning immobility are urgency, anxiety, drooling, pain, depression, paresthesia of the extremities, and dizziness.
[0177] Other symptoms recently associated with morning immobility include postprandial abdominal bloating, abdominal discomfort, early satiety, nausea, vomiting, weight loss, and nutritional disorders.
[0178] As used herein, the terms "treatment" and "treating" refer to the management and care of a patient to combat a condition, disease or disorder. The term is intended to include the overall treatment of a given condition from which a patient suffers, e.g., the administration of a composition to relieve or alleviate symptoms or complications and / or to prevent the condition, disease or disorder; "Preventing" is understood to refer to the management and care of a patient to hinder the onset of a condition, disease or disorder, and includes the administration of a composition to prevent or reduce the risk of development of symptoms or complications. The patient to be treated is preferably a mammal, particularly a human.
[0179] The terms "Parkinson's disease," "Parkinson," and "PD" refer to a neurological syndrome characterized by dopamine deficiency resulting from degenerative, vascular, or inflammatory changes in the basal ganglia of the substantia nigra. The terms also refer to syndromes that resemble Parkinson's disease, but may or may not be attributable to Parkinson's disease, such as parkinsonian side effects caused by certain antipsychotic medications.
[0180] In one embodiment, the composition is administered in a therapeutically effective amount.As used herein, a therapeutically effective amount refers to an amount sufficient to cure, alleviate, prevent, reduce the risk of, or partially suppress the clinical symptoms of certain diseases or disorders and their complications, particularly morning immobility in Parkinson's disease patients.
[0181] In one embodiment, the pharmaceutical composition is administered before sleep. In one embodiment, the pharmaceutical composition is administered once daily before sleep.
[0182] In one embodiment, the pharmaceutical composition is administered before bedtime. In one embodiment, the pharmaceutical composition is administered once daily before bedtime.
[0183] In one embodiment, the pharmaceutical composition is administered 4 to 0 hours before sleep, for example, 4 to 3.5 hours before sleep, for example, 3.5 to 3 hours before, for example, 3 to 2.5 hours before, for example, 2.5 to 2 hours before, for example, 2 to 1.5 hours before, for example, 1.5 to 1 hour before, for example, 1 hour to 45 minutes before, for example, 45 to 30 minutes before, for example, 30 to 20 minutes before, for example, 20 to 15 minutes before, for example, 15 to 10 minutes before, for example, 10 to 5 minutes before, for example, 5 to 1 minute before, for example, 1 minute to 0 minutes before.
[0184] In one embodiment, the pharmaceutical composition is administered 4 to 0 hours before going to bed, for example, 4 hours to 3.5 hours, for example, 3.5 hours to 3 hours, for example, 3 hours to 2.5 hours, for example, 2.5 hours to 2 hours, for example, 2 hours to 1.5 hours, for example, 1.5 hours to 1 hour, for example, 1 hour to 45 minutes, for example, 45 minutes to 30 minutes, for example, 30 minutes to 20 minutes, for example, 20 minutes to 15 minutes, for example, 15 minutes to 10 minutes, for example, 10 minutes to 5 minutes, for example, 5 minutes to 1 minute, for example, 1 minute to 0 minutes.
[0185] In one embodiment, the pharmaceutical composition is administered in combination with an immediate release levodopa product and / or a controlled release levodopa product.
[0186] Further Active Pharmaceutical Ingredients In one embodiment, the pharmaceutical composition further comprises, separately or together, one or more additional active pharmaceutical ingredients, which may be present in a first dosage form containing levodopa, in a second dosage form containing a dopa decarboxylase inhibitor, or in a third dosage form.
[0187] In one embodiment, the further active pharmaceutical ingredient is dopamine; dopamine receptor agonists, such as bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, lisuride and derivatives thereof; catechol-O-methyltransferase (COMT) inhibitors, such as tolcapone and entacapone; apomorphine, such as apomorphine injection; NMDA antagonists, such as amantadine (Symmetrel); MAO-B inhibitors, such as selenium; gyline and rasagiline; serotonin receptor modulators; kappa opioid receptor agonists, such as TRK-820 ((E)-N-[17-cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6β-yl)]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride); GABA modulators; modulators of neuronal potassium channels, such as flupirtine and retigabine; and glutamate receptor modulators.
[0188] In one embodiment, the pharmaceutical composition is administered in combination with other pharmaceutical compositions containing levodopa having immediate and controlled release characteristics to achieve pharmacologically active levels of levodopa for extended periods of time, such as approximately 1-8 hours, thereby significantly reducing dosing frequency for the majority of Parkinson's disease patients compared to currently used products.
[0189] In one embodiment, the pharmaceutical composition is administered in combination with an immediate release product containing levodopa and / or in combination with a controlled release product containing levodopa.
[0190] In one embodiment, the pharmaceutical composition is administered in combination with one or more products selected from the group consisting of Sinemet, Pharmacopa, Atamet, Stalevo, Madopar, Prolopa, Parcopa, Lodosyn, Modopar, Madopark, Neodopasol, EC-Doparyl, Aldomet, Aldoril, Dopamet and Dopegyt.
[0191] In one embodiment, the pharmaceutical composition disclosed herein and the additional active pharmaceutical ingredient are administered simultaneously, separately or sequentially.
[0192] Complete set of parts The present disclosure also provides kits of parts that are useful for treating morning immobility as described herein.
[0193] A kit according to the present disclosure comprises a pharmaceutical composition as defined herein for the treatment, prevention or alleviation of morning immobility. The kit allows for simultaneous, sequential or separate administration of the pharmaceutical composition as described herein with one or more additional active pharmaceutical ingredients.
[0194] Working Example Example 1 Lactose was mixed with microcrystalline cellulose, sodium starch glycolate, and model compound (nicotinamide) in a tumble mixer for 5 minutes. Magnesium stearate was then added and mixed for 30 seconds. The mixture was compressed into tablets. Each tablet had a tablet weight of 6.6 mg and a size of 2 mm, holding 0.28 mg of model compound each. The thickness of the tablets was approximately 1.7 mm.
[0195] [Table 1]
[0196] Model compound mini-tablets were film-coated in a fluidized bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For a 325 g core tablet, 1000 g of film solution was produced, including a 10% excess for production losses, to allow film-coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 28-30°C. 682.0 g, 784.9 g and 853.1 g of film solution were applied to reach the desired tablet weight gains of 20%, 23% and 25%, respectively.
[0197] [Table 2]
[0198] Forty-four mini-tablets were tested for dissolution using the USP2 Paddle Apparatus (USP Paddle Dissolution Test Method). Each vessel was filled with 600 mL of isotonic saline and rotated at 75 rpm. The collected samples were quantified using a spectrophotometer at 260 nm. The results are shown in Figure 2.
[0199] Example 2 The mini-tablets from Example 1 were film-coated in a fluid bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For a 325 g core tablet, 1000 g of film solution was produced, including a 10% excess for production losses, to allow film-coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 28-29° C. 341.3 g, 511.9 g, 682.5 g and 853.1 g of film solution were applied to reach the desired tablet weight gains of 10%, 15%, 20% and 25%, respectively.
[0200] [Table 3]
[0201] 44 mini-tablets were tested for dissolution using a USP2 Paddle apparatus. Each vessel contained 600 mL of isotonic saline and rotated at 75 rpm. Recovered samples were quantified using a spectrophotometer at 260 nm. The results are shown in Figure 3A.
[0202] Example 3 The minitablets from Example 1 were film coated as described in Example 2 using the following film composition:
[0203] [Table 4]
[0204] The minitablets were tested as described in Example 2 and the results are shown in Figure 3B.
[0205] Example 4 The minitablets from Example 1 were film coated as described in Example 2 using the following film composition:
[0206] [Table 5]
[0207] The minitablets were tested as described in Example 2 and the results are shown in Figure 4A.
[0208] Example 5 The minitablets from Example 1 were film coated as described in Example 2 using the following film composition:
[0209] [Table 6]
[0210] The minitablets were tested as described in Example 2 and the results are shown in Figure 4B.
[0211] Example 6 Levodopa was mixed with microcrystalline cellulose, sodium starch glycolate, and pregelatinized starch in a 1 L high shear mixer for 2 minutes. Purified water was added slowly over 3-4 minutes with mixing until adequate moisture was achieved, then granulated for 2 minutes. The resulting granules were dried at 40°C overnight and sieved through a 0.6 mm screen.
[0212] [Table 7]
[0213] The resulting levodopa granules were mixed with sodium starch glycolate and magnesium stearate.
[0214] [Table 8]
[0215] The mixture was compressed into tablets, each tablet having a tablet weight of 6.15 mg and a size of 2 mm, each tablet holding 2.8 mg of levodopa, and the thickness of the tablets was approximately 1.7 mm.
[0216] [Table 9]
[0217] Levodopamine mini tablets were film coated in a fluidized bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For a 320 g core tablet, 900 g of film solution was produced, including a 10% excess for production losses, to allow film coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 27-29°C. 336.0 g, 504.0 g, 672.0 g and 840.0 g of film solution were applied to reach the desired tablet weight gains of 10%, 15%, 20% and 25%, respectively.
[0218] [Table 10]
[0219] 100 mg of levodopa corresponds to approximately 35 mini-tablets.
[0220] Example 7 Levodopa was mixed with microcrystalline cellulose, sodium starch glycolate, and pregelatinized starch in a 1 L high shear mixer for 2 minutes. Purified water was added slowly over 3-4 minutes with mixing until adequate moisture was achieved, then granulated for 2 minutes. The resulting granules were dried at 40°C overnight and sieved through a 0.6 mm screen.
[0221] [Table 11]
[0222] The resulting levodopa granules were mixed with sodium starch glycolate and magnesium stearate. The mixture was compressed into tablets. Each tablet had a tablet weight of 6.4 mg, a size of 2 mm, and held 3.0 mg of levodopa each. The thickness of the tablets was approximately 1.7 mm.
[0223] [Table 12]
[0224] Levodopamine mini tablets were film coated in a fluidized bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For a 300 g core tablet, 900 g of film solution was produced, including a 10% excess for production losses, to allow film coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 27-29°C. 551.3 g, 630.0 g, 708.8 g and 787.5 g of film solution were applied to reach the desired tablet weight gains of 17.5%, 20.0%, 22.5% and 25%, respectively.
[0225] [Table 13]
[0226] 100 mg of levodopa corresponds to approximately 33 mini-tablets.
[0227] Example 8 The mini-tablets from Example 6 were tested for dissolution using a USP2 Paddle apparatus. A mini-tablet equivalent to 100 mg of levodopa was tested in each vessel using 600 ml of isotonic saline and 75 rpm. The collected samples were quantified using a spectrophotometer at 284 nm. The results (solid line) along with those from Example 5 (dotted line) are shown in Figure 6, showing similar release from levodopa compared to the model compound.
[0228] Example 9 The mini-tablets from Example 7 were tested for dissolution using a USP2 Paddle apparatus. A mini-tablet equivalent to 100 mg of levodopa was tested in each vessel using 600 ml of isotonic saline and 75 rpm. The collected samples were quantified using a spectrophotometer at 284 nm. The results are shown in Figure 5.
[0229] Example 10 Levodopa was mixed with microcrystalline cellulose, sodium starch glycolate, and pregelatinized starch in a 1 L high shear mixer for 2 minutes. Purified water was added slowly over 3-4 minutes with mixing until adequate moisture was achieved, then granulated for 2 minutes. The resulting granules were dried at 40°C overnight and sieved through a 0.6 mm screen.
[0230] [Table 14]
[0231] The resulting levodopa granules were mixed with sodium starch glycolate and magnesium stearate. The mixture was compressed into tablets. Each tablet had a tablet weight of 5.75 mg, a size of 2 mm, and held 4.0 mg of levodopa each. The thickness of the tablets was approximately 1.6 mm.
[0232] [Table 15]
[0233] Levodopa minitablets were fluid bed film coated with a semipermeable film as described in Example 6. 100 mg of levodopa corresponds to approximately 44 minitablets.
[0234] The minitablets were tested for dissolution as described in Example 8. The results are shown in Figure 7 and show poor control release and poor burst release at low levels of superdisintegrant.
[0235] Example 11 Carbidopa was mixed with microcrystalline cellulose, sodium starch glycolate, and pregelatinized starch in a 1 L high shear mixer for 2 minutes. Purified water was added slowly over 3-4 minutes with mixing until adequate moisture was achieved, then granulated for 2 minutes. The resulting granules were dried at 40°C overnight and sieved through a 0.6 mm screen.
[0236] [Table 16]
[0237] The resulting carbidopa granules were mixed with sodium starch glycolate and magnesium stearate. The mixture was compressed into tablets. Each tablet had a tablet weight of 6.90 mg, a size of 2 mm, and held 2.5 mg of carbidopa each. The thickness of the tablets was approximately 1.9 mm.
[0238] [Table 17]
[0239] Carbidopamini tablets were film-coated in a fluidized bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For 300 g core tablets, 900 g of film solution was produced, including a 10% excess for production losses, to allow film-coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 27-29°C. 336.0 g, 504.0 g, 672.0 g and 840.0 g of film solution were applied to reach the desired tablet weight gains of 10%, 15%, 20% and 25%, respectively.
[0240] [Table 18]
[0241] 25 mg of carbidopa corresponds to approximately 10 mini-tablets.
[0242] Example 12 The mini-tablets from Example 11 were tested for dissolution using a USP2 Paddle apparatus. A mini-tablet equivalent to 25 mg of carbidopa was tested in each vessel using 600 ml of isotonic saline and 75 rpm. The collected samples were quantified using a spectrophotometer at 284 nm.
[0243] Example 13 Thirty-three levodopa mini-tablets coated to 25% weight gain from Example 7 and film coated carbidopa mini-tablets from Example 11 were mixed and filled into hard shell gelatin capsules, size 0. The capsules hold a dose of levodopa 100 mg + carbidopa 25 mg, with the active ingredients released after a lag time, with carbidopa followed by levodopa.
[0244] Example 14 Morning immobility, Phase I PK study A randomized, open-label, crossover study to evaluate the single-dose pharmacokinetic properties and relative bioavailability of several selected test formulations containing carbidopa and L-dopa in healthy subjects.
[0245] The primary endpoint is to evaluate the single-dose pharmacokinetic (PK) characteristics and relative bioavailability of several selected experimental pulsatile release formulations containing carbidopa and L-dopa.
[0246] The following will be assessed: Concentration-time data from plasma will be used to calculate applicable PK parameters for L-dopa and carbidopa, including maximum plasma levels (Cmax and Tmax).
[0247] Example 15 Morning Immobility, Phase Ib, Efficacy / Safety and PK Study A randomized, double-blind, placebo-controlled, crossover study to evaluate the short-term efficacy and safety and pharmacokinetic properties of single doses of several selected test formulations containing carbidopa and L-dopa in patients with Parkinson's disease presenting with morning immobility.
[0248] The primary endpoint is to evaluate the efficacy (short-term) of single doses of several selected experimental pulsatile release formulations containing carbidopa and L-dopa.
[0249] The following will be assessed: Assessment of Parkinsonian symptoms in the morning hours when morning immobility is usually observed (using the UPDRS scale) after treatment with selected test agents containing carbidopa and L-dopa.
[0250] Example 10 Carbidopa was mixed with microcrystalline cellulose, sodium starch glycolate, and pregelatinized starch in a 1 L high shear mixer for 2 minutes. A solution of pregelatinized starch in purified water was added slowly over 2-3 minutes with mixing until adequate moisture was achieved, then granulated for 1 minute. The resulting granules were dried in a STREA fluid bed at approximately 60°C to a water activity of 20% or less, and sieved through a 1.4 mm screen.
[0251] [Table 19]
[0252] The resulting carbidopa granules were mixed with sodium starch glycolate and magnesium stearate. The mixture was compressed into tablets. Each tablet had a tablet weight of about 7.20 mg, a size of 2 mm, and held 2.6 mg of carbidopa each. The thickness of the tablets was approximately 1.8 mm.
[0253] [Table 20]
[0254] Carbidopamini tablets were film-coated in a fluidized bed with an ethylcellulose-based semipermeable film. The film composition is shown in the table below. For 300 g core tablets, 900 g of film solution was produced, including a 5% excess for production losses, to allow film-coating with a tablet weight increase of up to 25.0% if desired. Spray conditions were adjusted to an outlet air temperature of 27-29°C. 441.0 g, 514.5 g, 588.0 g, 661.5 g and 735.0 g of film solution were applied to reach the desired tablet weight gains of 15%, 17.5%, 20%, 22.5% and 25%, respectively.
[0255] [Table 21]
[0256] 25 mg of carbidopa corresponds to approximately 10 mini-tablets.
[0257] Example 11 The mini-tablets from Example 16 were tested for dissolution using a USP2 Paddle apparatus. A mini-tablet equivalent to 25 mg of carbidopa was tested in each vessel using 600 ml of isotonic saline and 75 rpm. The collected samples were quantified using a spectrophotometer at 284 nm. The results are shown in Figure 8.
Claims
1. i) levodopa and a dopa decarboxylase inhibitor, ii) a pulsatile release component that provides a pulsed release of said levodopa and said dopa decarboxylase inhibitor following a predetermined delay period; 1. A pulsatile release pharmaceutical composition comprising:
2. i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and A pulsatile pharmaceutical composition comprising, separately or together:
3. i) a first pulsatile release component comprising levodopa, said first pulsatile release component providing a pulsed release of levodopa following a predetermined delay; ii) a second pulsatile release component comprising a dopa decarboxylase inhibitor, said second pulsatile release component providing a pulsed release of said dopa decarboxylase inhibitor following a predetermined delay period; and A pulsatile release pharmaceutical composition comprising, separately or together, A pulsatile release pharmaceutical composition, wherein the lag time of the first pulsatile release component comprising levodopa is longer than the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the dopa decarboxylase inhibitor is selected from the group consisting of carbidopa, benserazide, methyldopa and DFMD (α-difluoromethyl-dopa), or a pharma- ceutically acceptable derivative thereof.
5. 5. The pharmaceutical composition of any of claims 1 to 4, wherein the levodopa comprises pharma- ceutically acceptable derivatives of levodopa, including but not limited to levodopa methyl ester and levodopa prodrugs, such as XP21279, and modified levodopa, such as deuterated levodopa.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein the pulsatile release composition is a time-controlled pulsatile release system, including a bulk erosion system and a surface erosion system.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the pharmaceutical composition is in a pharmaceutical dosage form.
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the pharmaceutical dosage form is a solid dosage form, an oral dosage form, and / or an oral solid dosage form.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the pharmaceutical composition is in a multiparticulate form.
10. The pharmaceutical composition has two dosage forms: i) a first dosage form that provides a pulsatile release of levodopa following a predetermined delay period; ii) a second dosage form that provides a pulsed release of a dopa decarboxylase inhibitor following a predetermined delay period; A multiparticulate dosage form comprising, separately or together, 10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the lag time of the first dosage form optionally comprising levodopa is longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor.
11. The pharmaceutical composition according to any of claims 1 to 10, wherein the multiparticulate dosage form is packaged in a capsule, pouch, sachet or stick pack.
12. i) the delay time of the pulsatile release component is adjusted to release the levodopa and the dopa decarboxylase inhibitor in the small intestine, such as the lower part of the small intestine; and / or ii) the delay time of the first pulsatile release component comprising levodopa and the delay time of the second pulsatile release component comprising a dopa decarboxylase inhibitor are adjusted to release the levodopa and the dopa decarboxylase inhibitor in the small intestine, such as the lower portion of the small intestine; The pharmaceutical composition according to any one of claims 1 to 11.
13. i) the lag time of the pulsatile release component comprising levodopa and a dopa decarboxylase inhibitor is between 2-8 hours, such as 2-3 hours, such as 3-4 hours, such as 4-5 hours, such as 5-6 hours, such as 6-7 hours, such as 7-8 hours; ii) the lag time of the first pulsatile release component comprising levodopa is between 2 and 8 hours, such as 2 to 3 hours, such as 3 to 4 hours, such as 4 to 5 hours, such as 5 to 6 hours, such as 6 to 7 hours, such as 7 to 8 hours, and / or iii) the lag time of the second pulsatile release component comprising a dopa decarboxylase inhibitor is between 2-8 hours, such as 2-3 hours, such as 3-4 hours, such as 4-5 hours, such as 5-6 hours, such as 6-7 hours, such as 7-8 hours; A pharmaceutical composition according to any one of claims 1 to 12.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the lag time of the first dosage form containing levodopa is 5 to 90 minutes longer than the lag time of the second dosage form containing a dopa decarboxylase inhibitor, such as 5 to 10 minutes longer, such as 10 to 15 minutes longer, such as 15 to 20 minutes longer, such as 20 to 25 minutes longer, such as 25 to 30 minutes longer, such as 30 to 35 minutes longer, such as 35 to 40 minutes longer, such as 40 to 45 minutes longer, such as 45 to 50 minutes longer, such as 50 to 55 minutes longer, such as 55 to 60 minutes longer, such as 60 to 65 minutes longer, such as 65 to 70 minutes longer, such as 70 to 75 minutes longer, such as 75 to 80 minutes longer, such as 80 to 85 minutes longer, such as 85 to 90 minutes longer, etc.
15. 15. The pharmaceutical composition of any of claims 1 to 14, wherein the lag time of the first dosage form comprising levodopa is at least 5 minutes longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor, such as at least 10 minutes longer, such as at least 15 minutes longer, such as at least 20 minutes longer, such as at least 25 minutes longer, such as at least 30 minutes longer, such as at least 35 minutes longer, such as at least 40 minutes longer, such as at least 45 minutes longer, such as at least 50 minutes longer, such as at least 55 minutes longer, such as at least 60 minutes longer than the lag time of the second dosage form comprising a dopa decarboxylase inhibitor.
16. 16. The pharmaceutical composition of any of claims 1 to 15, wherein the pharmaceutical composition releases 70-100% of the drug load measured 2-5 hours after the lag phase, i.e., releases 70-100% of the levodopa and / or dopa decarboxylase inhibitor measured 2-5 hours after the lag phase.
17. The pharmaceutical composition according to any of claims 1 to 16, wherein said pharmaceutical dosage form is selected from the group consisting of tablets, mini-tablets, micro-tablets, spheres, pellets, granules and capsules.
18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the pharmaceutical dosage form comprises a coating.
19. 19. The pharmaceutical composition according to any of claims 1 to 18, wherein the pharmaceutical dosage form is selected from the group consisting of coated tablets, coated minitablets, coated microtablets, coated spheres, coated pellets, coated granules and coated capsules.
20. 20. The pharmaceutical composition of any of claims 1 to 19, wherein the pharmaceutical dosage form comprises a soluble core, such as a soluble and swellable core, and a coating.
21. The pharmaceutical composition according to any one of claims 1 to 20, wherein the coating is a film coating.
22. The coating i) a semi-permeable, insoluble coating; or ii) Ruptureable insoluble coating The pharmaceutical composition according to any one of claims 1 to 21, wherein the coating is an insoluble coating such as
23. The pharmaceutical composition according to any of claims 1 to 22, wherein the insoluble coating comprises a film-forming polymer and / or a water-insoluble polymer.
24. The pharmaceutical composition according to any of claims 1 to 23, wherein the semi-permeable, insoluble coating comprises a water-insoluble polymer and a pore-forming agent, such as a hydrophilic pore-forming agent.
25. 25. The pharmaceutical composition according to any of claims 1 to 24, wherein the coating ratio of said film forming polymer or water insoluble polymer to said hydrophilic pore former is about 10 / 90, 15 / 85, 20 / 80, 25 / 75 or 30 / 70.
26. 26. The pharmaceutical composition according to any of the preceding claims, wherein the film-forming polymer and / or water-insoluble polymer is selected from the group consisting of ethyl cellulose, hydroxypropyl cellulose, cellulose acetate, acrylic polymers, enteric polymers, hypromellose acetate succinate, shellac, waxes and ethyl cellulose dispersants.
27. 27. The pharmaceutical composition of any of claims 1 to 26, wherein the pore former is selected from the group consisting of polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG).
28. The pharmaceutical composition according to any one of claims 1 to 27, wherein the coating is a dissolvable coating.
29. 29. The pharmaceutical composition of any of claims 1 to 28, wherein the pharmaceutical dosage form comprises a coated tablet containing levodopa and / or a dopa decarboxylase inhibitor and providing a pulsatile release of said levodopa and said dopa decarboxylase inhibitor following a predetermined delay period.
30. The pharmaceutical composition i) a coated tablet containing levodopa that provides a pulsatile release of levodopa following a predetermined delay period; ii) a coated tablet containing a dopa decarboxylase inhibitor that provides a pulsatile release of the dopa decarboxylase inhibitor following a predetermined delay period; 30. The pharmaceutical composition according to any one of claims 1 to 29, wherein the lag time of the coated tablet containing levodopa is longer than the lag time of the coated tablet containing a dopa decarboxylase inhibitor.
31. The pharmaceutical composition according to any one of claims 1 to 30, wherein the coated tablet is a coated mini tablet.
32. A pharmaceutical composition according to any of claims 1 to 31, wherein the coated mini-tablets are compressed to form a tablet.
33. The dosage form comprises or consists of a core and a coating, and the core i) levodopa and / or dopa decarboxylase inhibitors, ii) superdisintegrants; iii) one or more excipients, and iv) Optionally, an anti-adherent agent The pharmaceutical composition according to any one of claims 1 to 32, comprising:
34. the first pulsatile release component i) 25-75% by weight levodopa, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight, such as 50-55% by weight, such as 60-65% by weight, such as 65-70% by weight, such as 70-75% by weight levodopa; ii) 15-50% by weight of superdisintegrant, such as 15-20% by weight, such as 20-25% by weight, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight of superdisintegrant; iii) 10-50% by weight of excipients, such as 10-15% by weight, such as 15-20% by weight, such as 20-25% by weight, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight of excipients; iv) 0-2 wt. % of an anti-adherent, such as 0.25-0.50 wt. % of an anti-adherent, such as 0.50-0.75 wt. %, such as 0.75-1.0 wt. %, such as 1.0-1.25, such as 1.25-1.50, such as 1.50-1.75 wt. %, such as 1.75-2.0 wt. % of an anti-adherent; a minitablet core comprising or consisting of Coating and 34. The pharmaceutical composition according to any one of claims 1 to 33, which is a coated mini-tablet comprising:
35. 35. The pharmaceutical composition of any of claims 1 to 34, wherein the minitablet core comprises 1 to 5 mg levodopa, such as 1 to 1.25 mg, such as 1.25 to 1.5 mg, such as 1.5 to 1.75 mg, such as 1.75 to 2 mg, such as 2 to 2.25 mg, such as 2.25 to 2.5 mg, such as 2.5 to 2.75 mg, such as 2.75 to 3 mg, such as 3 to 3.25 mg, such as 3.25 to 3.5 mg, such as 3.5 to 3.75 mg, such as 3.75 to 4 mg, such as 4 to 4.25 mg, such as 4.25 to 4.5 mg, such as 4.5 to 4.75 mg, such as 4.75 to 5 mg levodopa.
36. the second pulsatile emission component i) 25-75% by weight of a dopa decarboxylase inhibitor, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight, such as 50-55% by weight, such as 60-65% by weight, such as 65-70% by weight, such as 70-75% by weight of a dopa decarboxylase inhibitor; ii) 15-50% by weight of superdisintegrant, such as 15-20% by weight, such as 20-25% by weight, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight of superdisintegrant; iii) 10-50% by weight of excipients, such as 10-15% by weight, such as 15-20% by weight, such as 20-25% by weight, such as 25-30% by weight, such as 30-35% by weight, such as 35-40% by weight, such as 40-45% by weight, such as 45-50% by weight of excipients; iv) 0-2 wt. % of an anti-adherent, such as 0.25-0.50 wt. % of an anti-adherent, such as 0.50-0.75 wt. %, such as 0.75-1.0 wt. %, such as 1.0-1.25, such as 1.25-1.50, such as 1.50-1.75 wt. %, such as 1.75-2.0 wt. % of an anti-adherent; a minitablet core comprising or consisting of Coating and 36. The pharmaceutical composition according to any one of claims 1 to 35, which is a coated mini-tablet comprising:
37. 37. The pharmaceutical composition according to any of claims 1 to 36, wherein the superdisintegrant is selected from the group consisting of crosslinked starches such as sodium starch glycolate, crosslinked celluloses such as croscarmellose sodium and low substituted hydroxypropyl cellulose (L-HPC), crosslinked PVP (polyvinylpyrrolidone) such as crospovidone, crosslinked alginic acid, soy polysaccharides, calcium silicate, gellan gum and xanthan gum.
38. 38. The pharmaceutical composition according to any one of claims 1 to 37, wherein the excipient comprises or comprises many of the group consisting of binders, liquid binders, fillers, solid carriers, diluents, flavourings, solubilizers, lubricants, glidants, suspending agents, preservatives, anti-adherents, wetting agents, disintegrants and adsorbents or combinations thereof.
39. The pharmaceutical composition according to any one of claims 1 to 37, wherein the excipient comprises any one of the group consisting of binders, liquid binders, fillers, solid carriers, diluents, flavourings, solubilizers, lubricants, glidants, suspending agents, preservatives, anti-adherents, wetting agents, disintegrants and adsorbents or combinations thereof.
39. 39. The pharmaceutical composition of any of claims 1-38, wherein the binder is selected from the group consisting of acacia, alginic acid, carbomer, sodium carboxymethylcellulose, carrageenan, cellulose acetate phthalate, chitosan, copovidone, dextrates, dextrin, dextrose, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropyl methylcellulose (HPMC or hypromellose), methylcellulose, microcrystalline cellulose (MCC), poloxamer, polydextrose, polyethylene oxide, povidone, sodium alginate, sucrose, starch, pregelatinized starch, and maltodextrin.
40. 40. The pharmaceutical composition of any of claims 1-39, wherein the excipient comprises a liquid binder selected from the group consisting of pregelatinized starch, hydroxypropylmethylcellulose (HPMC), methylcellulose and gelatin.
41. 41. The pharmaceutical composition of any of claims 1 to 40, wherein the excipients include binders and liquid binders, such as microcrystalline cellulose (MCC) and pregelatinized starch.
42. The excipient is i) 5-25% by weight of binder, such as 5-7.5% by weight, such as 7.5-10% by weight, such as 10-12.5% by weight, such as 12.5-15% by weight, such as 15-17.5% by weight, such as 17.5-20% by weight, such as 20-22.5% by weight, such as 22.5-25% by weight of binder; ii) 1-20% by weight of liquid binder, such as 1-2.5% by weight, such as 2.5-5% by weight, such as 5-7.5% by weight, such as 7.5-10% by weight, such as 10-12.5% by weight, such as 12.5-15% by weight, such as 15-17.5% by weight, such as 17.5-20% by weight of liquid binder; The pharmaceutical composition according to any one of claims 1 to 41, comprising:
43. 43. The pharmaceutical composition according to any of claims 1 to 42, wherein the anti-adherent agent is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, hydrogenated castor oil, hydrogenated vegetable oil, medium chain glycerides, palmitic acid, poloxamer, polyethylene glycol, stearic acid and talc.
44. The mini tablet cores i) 40-60% by weight, 45-55% by weight, etc. of levodopa; ii) 20-40% by weight, such as 25-35% by weight, of sodium starch glycolate; iii) 5 to 25% by weight, 10 to 20% by weight, or the like, of crystalline cellulose; iv) 1-20% by weight, such as 5-10% by weight, of pregelatinized starch; v) 0.5 to 1.5% by weight, e.g. 1% by weight, of magnesium stearate; A pharmaceutical composition according to any one of claims 1 to 43, comprising or consisting of:
45. 45. A pharmaceutical composition according to any of the preceding claims, wherein the coating is applied to increase the weight of the mini-tablet core by 10-40% by weight, such as 10-12.5% by weight, such as 12.5-15% by weight, such as 15-17.5% by weight, such as 17.5-20% by weight, such as 20-22.5% by weight, such as 22.5-25% by weight, such as 25-27.5% by weight, such as 27.5-30% by weight, such as 30-32.5% by weight, such as 32.5-35% by weight, such as 35-37.5% by weight, such as 37.5-40% by weight.
46. 46. A pharmaceutical composition according to any of the preceding claims, wherein the coating is applied to increase the weight of the tablet core by 1-20% by weight, such as 1-2.5% by weight, such as 2.5-5% by weight, such as 5-7.5% by weight, such as 7.5-10% by weight, such as 10-12.5% by weight, such as 12.5-15% by weight, such as 15-17.5% by weight, such as 17.5-20% by weight.
47. 47. The pharmaceutical composition of any one of claims 1 to 46, wherein the weight gain of the coating of the tablet core containing levodopa and the weight gain of the coating of the tablet core containing the dopa decarboxylase inhibitor are adjusted to release levodopa prior to the dopa decarboxylase inhibitor.
48. A pharmaceutical composition according to any of claims 1 to 47, wherein said composition further comprises one or more additional active pharmaceutical ingredients, either separately or together.
49. The further active pharmaceutical ingredient may be dopamine; a dopamine receptor agonist such as bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, lisuride, and derivatives thereof; a catechol-O-methyltransferase (COMT) inhibitor such as tolcapone and entacapone; an apomorphine, such as apomorphine injection; an NMDA antagonist such as amantadine (Symmetrel); an MAO-B inhibitor such as selegiline and rasagiline; a serotonin receptor modulator; 49. The pharmaceutical composition of any of claims 1 to 48, selected from the group consisting of kappa opioid receptor agonists such as RK-820 ((E)-N-[17-cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6β-yl)]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride); GABA modulators; modulators of neuronal potassium channels such as flupirtine and retigabine; glutamate receptor modulators; immediate release products containing levodopa and controlled release products containing levodopa.
50. The pharmaceutical composition according to any of claims 1 to 49, wherein said pharmaceutical composition and said further active pharmaceutical ingredient are administered simultaneously, separately or sequentially.
51. A pharmaceutical composition according to any one of claims 1 to 50 for use in the treatment of morning immobility in patients with Parkinson's disease.
52. 52. A pharmaceutical composition according to any one of claims 1 to 51 for use in the treatment of morning immobility in a patient with Parkinson's disease, wherein said composition is administered before sleep.
53. 53. A pharmaceutical composition according to any of claims 1 to 52 for use in the treatment of morning immobility in patients with Parkinson's disease, wherein said composition is administered in combination with an immediate release levodopa product and / or a sustained release levodopa product.
Citation Information
Patent Citations
Pulsatile drug delivery system for treating morning immobility.
JP7534354B2
